Researchers' Broadening use of SiDMAP Technology Continues to Accelerate
News May 29, 2006
SiDMAP has reported that the pace at which institutions and researchers are adopting its proprietary metabolomics technology continues to accelerate, with six new project applications getting underway in the past five months.
SiDMAP recently has been hired to provide flux-based metabolomics data and analyses by researchers at BiPar Sciences, Inc. and two other major pharmaceutical companies as well as three extremely prestigious universities and leading healthcare centers.
Researchers at BiPar Sciences, Inc. led by Valeria Ossovskya, Ph.D. Associate Director, Pre-Clinical Development, are working with SiDMAP to gather metabolic flux information on a proprietary therapeutic compound BiPar is developing.
An in vitro study was performed and the initial results were provided to Dr. Ossovskya in two weeks.
"As a result of SiDMAP's work we have gained greater insight into this compound's mechanism of action," Dr. Ossovskya commented. "Their professionalism and effort exceeded our expectations."
"The fact that companies like BiPar and such prestigious academic institutions and health centers have chosen to work with SiDMAP merely reaffirms our belief that the quality and unique nature of the data we provide truly distinguish us from other metabolomic solution providers," said Agi Hirshberg, SiDMAP's President and Founder.
"In addition to these new customers, we are extremely proud that most of our initial customers are returning for additional projects and many are actively considering broader collaborations with us. When customers sign up for second and third projects, it truly validates the utility of our services."
SiDMAP is honoring the requests of the two other companies and three academic institutions to abstain from disclosing their identities and any of the financial terms of the agreements between the parties.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018